The Global Tacrolimus Market Is Expected To Grow Significantly, Driven By the Increasing Incidence of Organ Transplantation
Tacrolimus Market |
Tacrolimus Market,
by Product Type (Tacrolimus Capsules and Tablets, Tacrolimus Ointment,
Tacrolimus Injection, and Tacrolimus Granules), by Application
(Immunosuppression, Dermatitis, and Others), by End User (Organ Transplant
Centers, Hospitals, Clinics, and Others), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook,
and Opportunity Analysis, 2022 - 2030.
Market Overview:
Tacrolimus
is an immunosuppressive drug that is used to prevent organ rejection in
individuals who have received a kidney, liver, or heart transplant. It works by
suppressing the immune system, which helps to prevent the body from rejecting
the transplanted organ.
Tacrolimus
belongs to a class of drugs called calcineurin inhibitors. It is available in
various dosage forms, including capsules, ointments, and injections. The drug
is usually taken orally, and the dosage is adjusted based on the patient's age,
weight, and medical condition.
In
addition to its use in transplant patients, tacrolimus is also used in the
treatment of certain autoimmune diseases such as eczema and psoriasis. When
used as a topical ointment, tacrolimus can help to reduce inflammation and
itching associated with these skin conditions.
Competitive Landscape:
Major
players operating in the global Tacrolimus
Market include
Vibcare Pharma Pvt. Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Senju
Pharmaceutical Co. Ltd., Abbott, Pfizer Inc., Dr. Reddy's Laboratories Ltd.,
Astellas Pharma Inc., Mylan N.V., and Novartis AG.
Key Market Drivers:
The
rising prevalence of chronic diseases such as diabetes and kidney diseases has
led to an increase in the number of organ transplant procedures, which is
expected to augment the growth of the global tacrolimus market. For instance, according to the Global
Observatory on Donation and Transplantation, around 129,681 organ transplants
were performed globally in 2020. Topical tacrolimus ointments are widely used
in the treatment of skin diseases such as eczema and psoriasis, driving the demand
for tacrolimus.
The
increasing healthcare spending and improving healthcare infrastructure in
emerging markets such as China and India are estimated to enhance the growth of
the global Tacrolimus Market.
Covid-19 Impact Analysis:
The
COVID-19 pandemic has also led to an increase in demand in the global
tacrolimus market. Tacrolimus has been used as an immunosuppressant in COVID-19
patients to prevent cytokine storms and improve clinical outcomes. For
instance, in October 2020, Aequus Pharmaceuticals Inc. extended its promotional
service agreement with Sandoz Canada Inc. for the immediate release of
Tacrolimus.
Key Takeaways:
· North
America is expected to dominate the global tacrolimus market, owing to the high
prevalence of chronic diseases and the increasing number of organ transplant
procedures in the region. For instance, according to the Health Resources and
Services Administration, in 2021, over 40,000 transplants were performed in the
United States. The region is also home to major players in the tacrolimus
market, driving the growth of the global tacrolimus market.
· Asia-Pacific
is estimated to witness significant growth in the global Tacrolimus Market, driven by increasing healthcare spending,
improving healthcare infrastructure, and the rising prevalence of chronic
diseases in the region. China and India are the major contributors to the
growth of the market in the region. For instance, in November 2020, Lupin
Limited introduced Tacrolimus Capsules (5 mg, 1 mg, and 0.5 mg).
Comments
Post a Comment